126 related articles for article (PubMed ID: 20497745)
21. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers.
Friedrich C; Shi X; Zeng P; Ring A; Woerle HJ; Patel S
Int J Clin Pharmacol Ther; 2012 Dec; 50(12):889-95. PubMed ID: 23073142
[TBL] [Abstract][Full Text] [Related]
23. Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.
Barnett AH
Expert Opin Drug Saf; 2015 Jan; 14(1):149-59. PubMed ID: 25351273
[TBL] [Abstract][Full Text] [Related]
24. Relative bioavailability study of linagliptin/metformin tablets in healthy Chinese subjects.
Pichereau S; Zhao X; Cui Y; Zhao S; Hohl K; Meinicke T; Friedrich C
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):582-92. PubMed ID: 26073354
[TBL] [Abstract][Full Text] [Related]
25. Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials.
Metzmann K; Schnell D; Jungnik A; Ring A; Theodor R; Hohl K; Meinicke T; Friedrich C
Int J Clin Pharmacol Ther; 2014 Jul; 52(7):549-63. PubMed ID: 24755124
[TBL] [Abstract][Full Text] [Related]
26. The effects of simvastatin on the pharmacokinectics of sitagliptin.
Cerra M; Luo WL; Li SX; Matthews C; O'Neill EA; Wagner JA; Stoch SA; Anderson MS
J Popul Ther Clin Pharmacol; 2012; 19(3):e356-60. PubMed ID: 23077137
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers.
Macha S; Lang B; Pinnetti S; Broedl UC
Int J Clin Pharmacol Ther; 2014 Nov; 52(11):973-80. PubMed ID: 25161155
[TBL] [Abstract][Full Text] [Related]
28. Assessment of pharmacokinetic interaction between omega-3 carboxylic acids and the statins rosuvastatin and simvastatin: Results of 2 phase I studies in healthy volunteers.
Offman E; Davidson M; Nilsson C
J Clin Lipidol; 2017; 11(3):739-748. PubMed ID: 28506390
[TBL] [Abstract][Full Text] [Related]
29. [Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2012 Feb; 67(2):91-7. PubMed ID: 22482239
[TBL] [Abstract][Full Text] [Related]
30. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin.
Lilja JJ; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Oct; 68(4):384-90. PubMed ID: 11061578
[TBL] [Abstract][Full Text] [Related]
31. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
Neuvonen PJ; Kantola T; Kivistö KT
Clin Pharmacol Ther; 1998 Mar; 63(3):332-41. PubMed ID: 9542477
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of simvastatin lactone and its active metabolite simvastatin hydroxy acid in healthy Chinese male and female volunteers.
Yang W; Xu H; Song Y; Wang X; Ren X; Zhao D; Cai Y; Zhang S; Huang J; Zhang LR; Zhang T; Zuo M
Int J Clin Pharmacol Ther; 2014 Feb; 52(2):151-8. PubMed ID: 24290412
[TBL] [Abstract][Full Text] [Related]
33. Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects.
Prueksaritanont T; Vega JM; Zhao J; Gagliano K; Kuznetsova O; Musser B; Amin RD; Liu L; Roadcap BA; Dilzer S; Lasseter KC; Rogers JD
J Clin Pharmacol; 2001 May; 41(5):573-81. PubMed ID: 11361054
[TBL] [Abstract][Full Text] [Related]
34. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.
Lilja JJ; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1998 Nov; 64(5):477-83. PubMed ID: 9834039
[TBL] [Abstract][Full Text] [Related]
35. Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats.
Retlich S; Withopf B; Greischel A; Staab A; Jaehde U; Fuchs H
Biopharm Drug Dispos; 2009 Nov; 30(8):422-36. PubMed ID: 19771584
[TBL] [Abstract][Full Text] [Related]
36. Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux.
Fuchs H; Runge F; Held HD
Eur J Pharm Sci; 2012 Apr; 45(5):533-8. PubMed ID: 22198311
[TBL] [Abstract][Full Text] [Related]
37. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).
Graefe-Mody U; Friedrich C; Port A; Ring A; Retlich S; Heise T; Halabi A; Woerle HJ
Diabetes Obes Metab; 2011 Oct; 13(10):939-46. PubMed ID: 21672124
[TBL] [Abstract][Full Text] [Related]
38. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Tiwari A
Curr Opin Investig Drugs; 2009 Oct; 10(10):1091-104. PubMed ID: 19777398
[TBL] [Abstract][Full Text] [Related]
39. The concentration-dependent binding of linagliptin (BI 1356) and its implication on efficacy and safety.
Wright S; Singh RP; Retlich S; Graefe-Mody U; Derendorf H
Int J Clin Pharmacol Ther; 2012 May; 50(5):323-30. PubMed ID: 22541836
[TBL] [Abstract][Full Text] [Related]
40. Phase 1 and Pharmacokinetic Drug-Drug Interaction Study of Metformin, Losartan, and Linagliptin Coadministered With DW1029M in Healthy Volunteers.
Moon SJ; Kim SY; Lim CH; Jang HB; Kim MG; Jeon JY
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):408-419. PubMed ID: 27739231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
